Warning against Malaysia's vaccine production timeline

Skeptics caution that Malaysia's 2028 target for vaccine self-sufficiency may be overly optimistic and financially risky. Building a vaccine plant from scratch requires hundreds of millions in investment, with no guarantee of success. The technology is complex: vaccine production involves stringent quality controls, cold-chain logistics, and regulatory approvals that can take years. Even countries with advanced pharma sectors have struggled to launch new facilities on schedule. There is also the question of scale—Malaysia's domestic market may be too small to make production economically viable without government subsidies. If the plants run below capacity, costs per dose could exceed import prices. Moreover, the global vaccine market is dominated by a few large players, making it hard for a newcomer to compete. Critics worry that pouring funds into a high-risk venture could divert resources from other healthcare priorities, such as upgrading hospitals or training nurses. For the public, a failed project could mean higher taxes or budget cuts elsewhere. The plan also relies on technology transfer from foreign firms, which may come with restrictions or high royalty fees. Until clear milestones, cost estimates, and partnership agreements are made public, the 2028 deadline looks more like a hopeful target than a realistic plan.